Synergistic DNA-MVA prime-boost vaccination regimes for malaria and tuberculosis. by Gilbert, S, Moorthy, V, Andrews, L, Pathan, A, McConkey, S, Vuola, J, Keating, S, Berthoud, T, Webster, D, Mcshane, H, Hill, A

“…The T-cell responses induced by this prime-boost regime, in animals and humans, are substantially greater than the sum of the responses induced by DNA or MVA vaccines used alone, leading to the term introduced here of "synergistic" prime-boost immunisation. …”

Effective induction of HIV-specific CTL by multi-epitope using gene gun in a combined vaccination regime. by Hanke, T, Neumann, VC, Blanchard, T, Sweeney, P, Hill, A, Smith, G, McMichael, A

A viral vectored prime-boost immunization regime targeting the malaria Pfs25 antigen induces transmission-blocking activity. by Goodman, A, Blagborough, A, Biswas, S, Wu, Y, Hill, A, Sinden, R, Draper, S

“…Two immunizations were administered to mice in a heterologous prime-boost regime. Immunization of mice with AdHu5 Pfs25 at week 0 and MVA Pfs25 at week 10 (Ad-MVA Pfs25) resulted in high anti-Pfs25 IgG titers, consisting of predominantly isotypes IgG1 and IgG2a. …”

Enhancement of MHC class I-restricted peptide-specific T cell induction by a DNA prime/MVA boost vaccination regime. by Hanke, T, Blanchard, T, Schneider, J, Hannan, C, Becker, M, Gilbert, S, Hill, A, Smith, G, McMichael, A

“…It was found that previous immunological exposure to MVA reduced the efficiency of subsequent priming and boosting using the same vaccine vehicle. However, a combined regime whereby the animals were first primed with the DNA vaccine and then boosted with MVA was the most potent protocol for the induction of both interferon-gamma-producing and cytolytic T cells against two CTL epitopes simultaneously. …”

Enhanced CD8 T cell immunogenicity and protective efficacy in a mouse malaria model using a recombinant adenoviral vaccine in heterologous prime-boost immunisation regimes. by Gilbert, S, Schneider, J, Hannan, C, Hu, J, Plebanski, M, Sinden, R, Hill, A

“…Complete protective efficacy after intradermal immunisation was observed with the adenovirus prime-MVA boost regime. This study identifies recombinant replication-defective adenovirus as an alternative to recombinant replication-defective poxviruses as boosting agents for the induction of strong protective CD8(+) T cell responses.…”

Durability of immune responses induced by three leading candidate ebola vaccine regimes; rVSV ZEBOV, ChAd3 EBO Z-MVA BN-Filo and AdHu26.ZEBOV-MVA BN Filo by Ewer, K, Smith, C, Sarkar, E, Bowyer, G, Rampling, T, Mair, C, Bellamy, D, Sabir, S, Davies, C, Venkatraman, N, Conway-Jones, R, Campbell, D, Boyer, C, Hill, A, Thomson, E, Snape, M

Prime boost vaccination with viral vectors targeting apical membrane antigen1 by Biswas, S

“…In this murine malaria model, AdHu5 and MVA encoding AMA1 when used in a heterologous prime boost regime showed excellent immunogenicity, both humoral and cellular. …”

A human Phase I/IIa malaria challenge trial of a polyprotein malaria vaccine. by Porter, D, Thompson, F, Berthoud, T, Hutchings, C, Andrews, L, Biswas, S, Poulton, I, Prieur, E, Correa, S, Rowland, R, Lang, T, Williams, J, Gilbert, S, Sinden, R, Todryk, S, Hill, A

“…Following safety assessment of single doses, 15 volunteers received a heterologous prime-boost vaccination regime and underwent malaria sporozoite challenge. …”

A human phase I/IIa malaria challenge trial of a polyprotein malaria vaccine by Porter, D, Thompson, F, Berthoud, T, Hutchings, C, Andrews, L, Biswas, S, Poulton, I, Prieur, E, Correa, S, Rowland, R, Lang, T, Williams, J, Gilbert, S, Sinden, R, Todryk, S, Hill, A

“…Following safety assessment of single doses, 15 volunteers received a heterologous prime-boost vaccination regime and underwent malaria sporozoite challenge. …”

Immune responses against a liver-stage malaria antigen induced by simian adenoviral vector AdCh63 and MVA prime-boost immunisation in non-human primates by Capone, S, Reyes-Sandoval, A, Naddeo, M, Siani, L, Ammendola, V, Rollier, C, Nicosia, A, Colloca, S, Cortese, R, Folgori, A, Hill, A

“…Antibodies to TRAP were exceptionally high and maintained for a long period of time after the prime-boost regime. These results in non-human primates highlight the potential of this vaccination regime and encourage its future use in clinical trials. © 2010 Elsevier Ltd.…”

5T4 oncofoetal glycoprotein: an old target for a novel prostate cancer immunotherapy by Cappuccini, F, Pollock, E, Stribbling, S, Hill, A, Redchenko, I

“…ChAdOx1-MVA vaccinated mice were completely protected against subsequent B16 melanoma challenge, but in therapeutic settings this regime was only modestly effective in delaying tumour outgrowth. …”

Immune responses against a liver-stage malaria antigen induced by simian adenoviral vector AdCh63 and MVA prime-boost immunisation in non-human primates. by Capone, S, Reyes-Sandoval, A, Naddeo, M, Siani, L, Ammendola, V, Rollier, C, Nicosia, A, Colloca, S, Cortese, R, Folgori, A, Hill, A

“…Antibodies to TRAP were exceptionally high and maintained for a long period of time after the prime-boost regime. These results in non-human primates highlight the potential of this vaccination regime and encourage its future use in clinical trials.…”

Phase Ia clinical evaluation of the plasmodium falciparum blood-stage antigen MSP1 in ChAd63 and MVA vaccine vectors by Sheehy, S, Duncan, C, Elias, S, Collins, K, Ewer, K, Spencer, A, Williams, A, Halstead, F, Moretz, SE, Miura, K, Epp, C, Dicks, M, Poulton, I, Lawrie, A, Berrie, E, Moyle, S, Long, C, Colloca, S, Cortese, R, Gilbert, S, Nicosia, A, Hill, A, Draper, S

“…A phase Ia clinical trial was conducted in healthy adults of a ChAd63-MVA MSP1 heterologous prime-boost immunization regime. The vaccine was safe and generally well tolerated. …”

Phase Ia clinical evaluation of the Plasmodium falciparum blood-stage antigen MSP1 in ChAd63 and MVA vaccine vectors. by Sheehy, S, Duncan, C, Elias, S, Collins, K, Ewer, K, Spencer, A, Williams, A, Halstead, F, Moretz, SE, Miura, K, Epp, C, Dicks, MD, Poulton, I, Lawrie, A, Berrie, E, Moyle, S, Long, C, Colloca, S, Cortese, R, Gilbert, S, Nicosia, A, Hill, A, Draper, S

“…A phase Ia clinical trial was conducted in healthy adults of a ChAd63-MVA MSP1 heterologous prime-boost immunization regime. The vaccine was safe and generally well tolerated. …”

Enhancing the efficacy of viral vector blood-stage malaria vaccines by Forbes, E

“…Finally, it was found that using a strong early promoter to drive antigen expression enhances the immunogenicity of single administration MVA vaccines, but that this did not enhance post-boost immunogenicity in an Ad_MVA regime.</p>…”

Effective induction of high-titer antibodies by viral vector vaccines. by Draper, S, Moore, A, Goodman, A, Long, C, Holder, A, Gilbert, S, Hill, F, Hill, A

“…Here we show that a recombinant adenovirus-poxvirus prime-boost immunization regime (known to induce strong T cell immunogenicity) can also induce very strong antigen-specific antibody responses, and we identify a simple complement-based adjuvant to further enhance immunogenicity. …”

DNA-based vaccines for malaria: a heterologous prime-boost immunisation strategy. by Hill, A, Reece, W, Gothard, P, Moorthy, V, Roberts, M, Flanagan, K, Plebanski, M, Hannan, C, Hu, J, Anderson, R, Degano, P, Schneider, J, Prieur, E, Sheu, E, Gilbert, S

“…Here we review the identification of a heterologous prime-boost regime using DNA priming and recombinant modified vaccinia Ankara (MVA) boosting that induces high level T cell responses in both mice and non-human primates. …”

Enhanced immunogenicity for CD8+ T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara. by Schneider, J, Gilbert, S, Blanchard, T, Hanke, T, Robson, K, Hannan, C, Becker, M, Sinden, R, Smith, G, Hill, A

“…DNA priming followed by MVA boosting may provide a general immunization regime for induction of high levels of CD8+ T cells.…”

Boosting BCG with MVA85A: the first candidate subunit vaccine for tuberculosis in clinical trials. by Mcshane, H, Pathan, A, Sander, C, Goonetilleke, N, Fletcher, H, Hill, A

“…Heterologous prime-boost immunization regimes induce higher levels of cellular immunity than homologous boosting with the same vaccine. …”

Gene gun intradermal DNA immunization followed by boosting with modified vaccinia virus Ankara: enhanced CD8+ T cell immunogenicity and protective efficacy in the influenza and mal... by Dégano, P, Schneider, J, Hannan, C, Gilbert, S, Hill, A

“…The present study compares both routes for the induction of specific CD8+ T cell responses and protection using different prime-boost immunization regimes in the influenza and the malaria models. In the DNA/MVA regime, equally high CD8+ T cell responses and levels of protection are achieved using ten times less DNA when delivered with a gene gun compared to intramuscular injection.…”